NYSEAMERICAN:APHB Ampliphi Biosciences (APHB) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free APHB Stock Alerts $2.51 -0.16 (-5.99%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$2.51▼$2.8550-Day Range N/A52-Week Range$0.15▼$1.37Volume5,098 shsAverage Volume842,200 shsMarket Capitalization$84.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Ampliphi Biosciences alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Ampliphi Biosciences Stock (NYSEAMERICAN:APHB)AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Read More APHB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APHB Stock News HeadlinesOctober 24, 2023 | benzinga.comPacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, PredictionsJanuary 25, 2023 | finance.yahoo.comAkston Biosciences Strengthens Board with Addition of John T. PrestonApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.January 5, 2023 | benzinga.comSelecta Biosciences Stock (NASDAQ:SELB), Quotes and News SummaryOctober 27, 2021 | finance.yahoo.comAPHB: Case Study on AB-PA01 Presented at ISHLT Annual MeetingSee More Headlines Receive APHB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2019Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:APHB Previous SymbolAMEX:APHB CUSIPN/A CIK921114 Webwww.ampliphibio.com Phone+1-804-8272524FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,469,000Free FloatN/AMarket Cap$84.01 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Paul C. Grint (Age 61)CEO & Director Mr. Steven R. Martin (Age 58)Sr. VP & CFO Mr. Michael Scott Salka (Age 57)Consultant Key CompetitorsBiopharmxNYSEAMERICAN:BPMXNervGen PharmaOTCMKTS:NGENFKinnate BiopharmaNASDAQ:KNTEVistagen TherapeuticsNASDAQ:VTGNNGM BiopharmaceuticalsNASDAQ:NGMView All Competitors APHB Stock Analysis - Frequently Asked Questions How were Ampliphi Biosciences' earnings last quarter? Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) issued its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.07. What other stocks do shareholders of Ampliphi Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL) and Corbus Pharmaceuticals (CRBP). How do I buy shares of Ampliphi Biosciences? Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:APHB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampliphi Biosciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.